Phase 1 Study With the Vaccine Candidate Plasmodium Falciparum Malaria Protein (FMP012), an E.Coli-expressed Cell-Traversal Protein, Administered Intramuscularly in Healthy Malaria-Naive Adults.

Trial Profile

Phase 1 Study With the Vaccine Candidate Plasmodium Falciparum Malaria Protein (FMP012), an E.Coli-expressed Cell-Traversal Protein, Administered Intramuscularly in Healthy Malaria-Naive Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2013

At a glance

  • Drugs Malaria vaccine (Primary) ; Glycopyranosyl lipid adjuvant
  • Indications Falciparum malaria
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 06 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top